Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension

Circulation

Volumn 110, Issue 14, 2004, Pages 1996-2002

  Bátkai, Sándor ^a   Pacher, Pál ^a   Osei Hyiaman, Douglas ^a   Radaeva, Svetlana ^a   Liu, Jie ^a   Harvey White, Judith ^a   Offertáler, László ^a   Mackie, Ken ^b   Rudd, M Audrey ^c   Bukoski, Richard D ^c   Kunos, George ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

Blood pressure; Contractility; Endocannabinoids; Hypertension; Pharmacology

Indexed keywords

ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; ENZYME INHIBITION; HEART LEFT VENTRICLE CONTRACTILITY; HYDROLYSIS; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR ENDOTHELIUM; VASODILATATION;

AMIDOHYDROLASES; ANGIOTENSIN II; ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; BENZYL COMPOUNDS; BLOOD PRESSURE; BORNANES; CARBAMATES; ENDOTHELIUM, VASCULAR; HYPERTENSION; MALE; MODELS, CARDIOVASCULAR; MYOCARDIAL CONTRACTION; MYOCARDIUM; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, INBRED DAHL; RATS, INBRED SHR; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL; UP-REGULATION; VASCULAR RESISTANCE; VASODILATION; VENTRICULAR FUNCTION, LEFT;

EID: 20844454912     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000143230.23252.D2     Document Type: Article

References (40)

1. Lew EA. High blood pressure, other risk factors and longevity: the insurance viewpoint. Am J Med. 1973;55:281-294.
2. Vollmer RR, Cavero I, Ertel RJ, et al. Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol. J Pharm Pharmacol. 1974;26:186-198.
3. Lake KD, Compton DR, Varga K, et al. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther. 1997;281:1030-1037.
4. Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther. 1975;18:287-297.
5. Varga K, Lake K, Martin BR, et al. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol. 1995;278:279-283.
6. Járai Z, Wagner JA, Goparaju SK, et al. Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice. Hypertension. 2000;35:679-684.
7. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564.
8. Bonz A, Laser M, Kullmer S, et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol. 2003;41:657-664.
9. Gebremedhin D, Lange AR, Campbell WB, et al. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol. 1999;266:H2085-H2093.
10. Liu J, Gao B, Mirshahi F, et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J. 2000;346:835-840.
11. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-65.
12. Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999;283:401-404.
13. Járai Z, Wagner JA, Varga K, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA. 1999;96:14136-14141.
14. Calignano A, La Rana G, Beltramo M, et al. Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur J Pharmacol. 1997;337:R1-R2.
15. Kosersky DS. Antihypertensive effects of delta9-tetrahydrocannabinol. Arch Int Pharmacodyn. 1978;233:76-81.
16. Lake KD, Martin BR, Kunos G, et al. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension. 1997;29:1204-1210.
17. Imig JD, Zhao X, Capdevila JH, et al. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002;39:690-694.
18. Pacher P, Liaudet L, Bai P, et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation. 2003;107:896-904.
19. Pacher P, Liaudet L, Mabley J, et al. Pharmacologic inhibition of poly-(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol. 2002;40:1006-1016.
20. Ramirez-Gonzalez MD, Tchakarov L, Mosqueda Garcia R, et al. Beta-endorphin acting on the brainstem is involved in the antihypertensive action of clonidine and alpha-methyldopa in rats. Circ Res. 1983;53:150-157.
21. Wager-Miller J, Westenbroek R, Mackie K. Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids. 2002;121:83-89.
22. Liu J, Tian Z, Gao B, et al. Dose-dependent activation of antiapoptotic and proapoptotic pathways by ethanol treatment in human vascular endothelial cells: differential involvement of adenosine. J Biol Chem. 2002;277:20927-20933.
23. Wang L, Liu J, Harvey-White J, et al. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci USA. 2003;100:1393-1398.
24. Gravait BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA. 2001;98:9371-9376.
25. Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003;9:76-81.
26. De Lago E, Ligresti A, Ortar G, et al. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur J Pharmacol. 2004;484:249-257.
27. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400:452-457.
28. Deutsch DG, Goligorsky MS, Schmid PC, et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 1997;100:1538-1546.
29. Wagner JA, Járai Z, Bátkai S, et al. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol. 2001;423:203-210.
30. Ishac EJ, Jiang L, Lake KD, et al. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol. 1996;18:2023-2028.
31. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci. 2002;22:9612-9617.
32. Mukhopadhyay S, Chapnick BM, Hewlett AC, et al. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol. 2002;282: H2046-H2054.
33. Offertáler L, Mo FM, Batkai S, et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol. 2003;63:699-705.
34. Bukoski RD, Batkai S, Jarai Z, et al. CB(1) receptor antagonist SR141716A inhibits Ca(2+)-induced relaxation in CB(1) receptor-deficient mice. Hypertension. 2002;39:251-257.
35. Ford WR, Honan SA, White R, et al. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol. 2002;135:1191-1198.
36. Ho WS, Hiley V. Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol. 2003;138:1320-1332.
37. Li J, Kaminski NE, Wang DH. Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor. Hypertension. 2003;41:757-762.
38. Pacher P, Bátkai S, Kunos G. Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol (London). 2004;558:647-657.
39. Anand-Srivastava MB. Enhanced expression of inhibitory guanine nucleotide regulatory protein in spontaneously hypertensive rats: relationship to adenylate cyclase inhibition. Biochem J. 1992;288:79-85.
40. Cingolani OH, Yang XP, Cavasin MA, et al. Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats. Hypertension. 2003;41:249-254.